Knight Therapeutics Inc.
TSX : GUD

Knight Therapeutics Inc.
SIFI S.p.A.

SIFI S.p.A.

August 02, 2016 17:00 ET

SIFI S.p.A. and Knight Therapeutics Announce Canadian License Agreement for NETILDEX™

MONTREAL, CANADA--(Marketwired - Aug. 2, 2016) - S.I.F.I- Società Industria Farmaceutica Italiana S.p.A. ("SIFI"), a prominent Italian Eye Care company, and Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that they have entered into an agreement whereby Knight received the exclusive rights to commercialize NETILDEX™ in Canada. NETILDEX™ is a fixed combination of netilmicin and dexamethasone for the treatment of ocular inflammation of the anterior segment of the eye, in presence or at risk of bacterial infection. Under the terms of this agreement, Knight will also handle all ongoing regulatory and commercial activities for NETILDEX™ in Canada. Destum Partners acted as the advisor for SIFI on this agreement.

"We are pleased to partner with SIFI and add a unique product to our growing ophthalmology portfolio," said Jonathan Ross Goodman, President and Chief Executive Officer of Knight. "NETILDEX™ will offer patients and physicians a new antibiotic with a well-established corticosteroid in an innovative product line."

"We are pleased to be working with Knight, whom we believe is well positioned to help us bring NETILDEX™ to Canadian patients and physicians," said Mr. Fabrizio Chines, Chairman and Chief Executive Officer of SIFI. "The Knight team has a proven expertise in commercializing innovative pharmaceuticals in Canada and is assembling a nice portfolio of meaningful pharmaceuticals in ophthalmology."

About NETILDEX™

NETILDEX™ is a fixed combination of netilmicin and dexamethasone indicated for the treatment of ocular inflammation of the anterior segment of the eye, in presence or at risk of bacterial infection. NETILDEX™ has been successfully launched in Italy, Romania, Turkey, Mexico and Lebanon. Filing for regulatory approval in additional countries is ongoing.

NETILDEX™ is the first fixed combination product line available in single and multi-dose solution or single-dose hydrogel formulation. NETILDEX™ has been tested in over 600 patients in multiple Phase III studies and has been shown to be safe and effective in each clinical study.

About SIFI S.p.A.

SIFI is the leading Italian ophthalmic company, focused on eye care since 1935. SIFI designs, manufactures and markets innovative pharmaceutical specialty products, surgical and medical devices. Headquartered in Catania, Sicily, SIFI operates directly in Italy, Romania and Mexico with a staff of more than 350 people worldwide. Since June 2015, SIFI is backed by 21 Investimenti, a private equity firm founded by Alessandro Benetton, which supports the company's international expansion and portfolio development strategy.

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com.

Forward-Looking Statement

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2015. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.

Contact Information